Ruxolitinib treatment course among individual patients from the OPEN analysis set. AE, adverse event; BID, twice daily; HIRE, HealthCore Integrated Research Environment; NA, not available; OPEN, Oncology Provider Extended Network; QD, once daily. Patient-level data were not available from HIRE. ^†Physician assessed and reported. ^‡“Other” reasons were aggressive skin cancer surgery and patient request (n = 1 each).